Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.50
Bid: 1,756.00
Ask: 1,756.50
Change: -18.50 (-1.04%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,770.00
Low: 1,740.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

Fri, 29th Dec 2023 13:01

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

The FTSE 100 index closed up 10.50 points, 0.1%, at 7,733.24. The FTSE 250 ended down 29.53 points, 0.2%, at 19,689.63 and the AIM All-Share closed down 0.34 of a point at 763.32.

The Cboe UK 100 ended up 0.2% at 772.47, the Cboe UK 250 closed down 0.1% at 17,163.49, and the Cboe Small Companies ended up 0.7% at 14,992.05.

At the time of the early London market close, the CAC 40 in Paris was up 0.4%, while the DAX 40 in Frankfurt was up 0.3%, on track to add 15% and 19% respectively this year.

"The UK stock market has, once again, frustrated those who were convinced it was cheap and lived down the expectations of those who asserted it was cheap for good reason," said AJ Bell investment director AJ Bell commented last week.

In comparison to the double-digit returns offered elsewhere, the FTSE 100 offered a paltry 2.4% in 2023.

"However, that gain is supplemented by a dividend yield north of 3.5%, share buybacks and also mergers and acquisitions, so the total cash return will still be in the low double-digit percentage range. That beats inflation, government bond yields and returns on cash. The takeover activity witnessed in the UK again hints that there is value to be found, especially as many deals have been done at a big premium, and as we enter 2024 the UK market may still feature stocks that could appeal to a wide range of investor requirements and risk appetites."

Standout annual performances in the FTSE 100 came from Rolls-Royce, with the jet engine maker's shares tripling in value under the stewardship of its new chief executive Tufan Erginbilhic. Recent returnee to the large-cap index, Marks & Spencer, doubled the value of its shares amid robust trading despite a fairly downbeat consumer environment.

Dragging on the index were miners Anglo American and Fresnillo, losing 40% and 34% respectively. They faced headwinds from falling commodity prices amid a more downbeat assessment for China's economy, the country being a key importer of commodities.

Among its noteworthy stocks for 2024, AJ Bell points to GSK, with its shares closing the year flat, and Legal & General, which fell 0.1% this year.

Pharmaceutical firm GSK said the firm's relatively "static" share price over 2023, leads to a "tempting valuation".

"The relatively predictable demand, high margins and consistent cashflow that can result from a successful drug development model can also appeal at times of economic uncertainty, so GSK may appeal to those investors who fear that an unexpected recession could creep up on the UK equity market next year," AJB's Mould explained.

Meanwhile, life insurance, pensions and investment firm L&G might have its time in the sun, as borrowing costs wind down.

"The lowly valuation on an earnings basis, and forecast 8.5% dividend yield for 2024, offer the potential for capital appreciation and income generation, and management has a plan to increase its shareholder distribution by some 5% a year. Moreover, the balance sheet is strong," Mould noted.

The more domestically-focused FTSE 250 index, adding 2.9% in 2023, proved more resilient than many had expected amid the cost-of-living crisis and stagnant UK economic growth. It shed over 20% in 2022. Meanwhile, the AIM All-Share fell 9.0%, after plunging 31% in 2022.

On the UK front, there is expected to be a general election at some point in 2024. In the meantime, eyes will be on the March budget from Chancellor Jeremy Hunt, with analysts forecasting inheritance tax reform, cuts to fuel duty and income tax, and help for first-time home buyers.

All the while, the UK economy teeters on the edge of recession, as the latest official figures revealed 0.1% quarterly contraction for the third quarter. On a brighter note, inflation cooled more quickly than expected, dropping to 3.9% in November. Still, this remains well above the Bank of England's target of 2%, with Trading Economics forecasts indicating it will only cool to 3.0% by the third quarter of 2024.

The pound finishes the year on a much stronger footing, trading at USD1.2747, slightly higher than USD1.2741 at the London equities close on Thursday.

This is quite a jump from USD1.2054 at the end of 2022, and partly due to the more hawkish positioning of the BoE in comparison to the relatively dovish Fed.

The BoE is expected to begin a slow process of rate cuts from May, at the earliest. Following the Fed's December decision to keep rates on pause, the market rushed to price in at least 150 basis points of interest rate cuts in 2024 beginning from March. This has put selling pressure on the dollar in recent weeks.

The euro traded at USD1.1074, fading slightly from USD1.1078 – but firm on USD1.0686 at the end of 2022. Against the yen, the dollar was quoted at JPY141.42, up versus JPY141.08 – making strong annual gains on JPY131.84, as the Bank of Japan kept its ultra-loose monetary policy in place.

However, market expectations for the path of rates are markedly more dovish than those of the Fed itself. The central bank's latest quarterly dot plot showed that most officials expect rates to be in the range of 4.4% to 4.9% by the end of 2024. The federal funds rate currently stands at a 22-year high of 5.25% to 5.5%, so the dot plot is showing cuts of 100 basis points or less.

On Friday, the Dow Jones Industrial Average, the S&P 500, and the Nasdaq Composite were all called flat.

The Dow is up 14% so far in 2023, the S&P 500 up 25%, and the tech-heavy Nasdaq Composite is up 45%.

"The million-dollar question is what will happen next year. Of course, we don't know, nobody knows, and our crystal balls completely missed the AI rally that marked 2023, yet the general expectation is a cool down in the technology rally, and a rebalancing between the big tech stocks and the S&P493 on narrowing profit lead for the Magnificent 7 compared to the rest of the index in 2024," said Swissquote Bank senior analyst Ipek Ozkardeskaya.

The magnificent seven refers to Microsoft, Apple, Amazon, Meta, Google, Tesla and Nvidia – tech shares which generated almost all of the returns for the S&P 500 and Nasdaq 100.

Nvidia stole the show in 2023, amid the explosion of interest in artificial intelligence. Its shares leapt from USD147 at the beginning of the year to USD495 by the end.

Meanwhile, in commodities, oil prices have operated in a comparatively more stable range this year, after the volatility of 2022 amid the energy crisis prompted by Russia's invasion of Ukraine.

Brent oil was trading at USD77.56 a barrel early Friday, higher than USD78.70 late Thursday. Brent ended 2022 in London at USD83.21, so lost 6.8% over the course of 2023 – its first annual loss since 2020.

Fears of rising oil prices stemming from the conflict in the Middle East have failed to come to pass so far. Further, the waning efficacy of Opec+ alliance production cuts, mounting inventories, and a muted demand outlook continue to weigh on the outlook for oil. London's BP and Shell, which notched gains of 35% and 37% respectively last year, saw a more moderate performance. BP fell 3.7%, while Shell rose 8.6%.

Unlike the oil market, gold had a stellar 2023.

Spot gold has advanced 14% this year. It soared to an all-time record high of USD2,075 an ounce early this month. The precious metal has regained its lustre amid rising hopes that the Fed could pivot to monetary policy easing, and as it benefitted from its safe-haven status, thanks to geopolitical risks.

Dutch bank ING believes that safe-haven demand and the US interest rate outlook will keep gold supported in 2024, expecting the price to remain above the USD2,000 level next year. They even predict a new record high in 2024.

In next week's economic calendar, major financial markets, including the UK, US and Tokyo will remain closed on Monday to mark New Year's Day.

Tuesday brings the latest series of manufacturing PMIs, with services PMIs to follow on Thursday. On Wednesday there will be the US JOLTS and ADP jobs reports and the Federal Reserve's meeting minutes, followed by the closely-watched non-farm payrolls print on Friday.

In the UK corporate calendar, there will be a much-anticipated trading statement from Next on Thursday, which will set the bar for the UK retail sector's festive performance.

By Elizabeth Winter, Alliance News deputy news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.